To dissect the molecular mechanisms underlying the cancer-preventive effects of TGFBRi treatment in rat mammary glands, we performed RNA-seq of FACS-purified CD24+CD29high basal and CD24+CD29low luminal normal mammary epithelial cells collected from peripubertal rats at variable timepoints after 10 days of TGFBRi treatment. This evidence concerns the gene CD24 and cancer.